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Abstract
Background: PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune
checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-L1 IHC, each developed
with a different ICI. We set to test if next generation RNA sequencing (RNA-seq) is a robust method to determine PD-L1
mRNA expression levels and furthermore, efficacy of predicting response to ICIs as compared to routinely used,
standardized IHC procedures.
Methods: A total of 209 cancer patients treated on-label by FDA-approved ICIs, with evaluable responses were assessed for
PD-L1 expression by RNA-seq and IHC, based on tumor proportion score (TPS) and immune cell staining (ICS). A subset of
serially diluted cases was evaluated for RNA-seq assay performance across a broad range of PD-L1 expression levels.
Results: Assessment of PD-L1 mRNA levels by RNA-seq demonstrated robust linearity across high and low expression
ranges. PD-L1 mRNA levels assessed by RNA-seq and IHC (TPS and ICS) were highly correlated (p< 2e-16). Sub-analyses
showed sustained correlation when IHC results were classified as high or low by clinically accepted cut-offs (p< 0.01), and
results did not differ by tumor type or anti-PD-L1 antibody used. Overall, a combined positive PD-L1 result (≥1% IHC TPS
and high PD-L1 expression by RNA-Seq) was associated with a 2-to-5-fold higher overall response rate (ORR) compared to a
double negative result. Standard assessments of sensitivity, specificity, positive predictive value (PPV), and negative predictive
value (NPV) showed that a PD-L1 positive assessment for melanoma samples by RNA-seq had the lowest sensitivity (25%)
but the highest PPV (72.7%). Among the three tumor types analyzed in this study, the only non-overlapping confidence
interval for predicting response was for “RNA-seq low vs high” in melanoma.
Conclusions: Measurement of PD-L1 mRNA expression by RNA-seq is comparable to PD-L1 expression by IHC both
analytically and clinically in predicting ICI response. RNA-seq has the added advantages of being amenable to
standardization and avoidance of interpretation bias. PD-L1 by RNA-seq needs to be validated in future prospective ICI
clinical studies across multiple histologies.
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Background
Five trial-evaluated immunohistochemistry (IHC) assays
for the assessment of CD274 (best known as pro-
grammed death ligand-1, PD-L1) expression in
formalin-fixed paraffin-embedded (FFPE) samples have
been developed as companion and complementary diag-
nostics alongside immune checkpoint inhibitors (ICIs)
targeting PD-L1 and its main receptor (programmed cell
death 1, PDCD1, best known as PD-1) [1–5]. While
these tests measure PD-L1 protein levels, they differ by
antibody clone, staining platform, and scoring system.
For instance, while assessment of PD-L1 expression in
advanced gastric cancer or gastroesophageal junction
adenocarcinoma samples by the PD-L1 IHC 22C3
pharmDx assay uses a “combined positive score” or CPS
[6], testing metastatic non-small cell lung cancer
(NSCLC) patient samples relies on a “tumor proportion
score” or TPS [7]. This variability in scoring methods
has contributed to confounding results across clinical
trials and in clinical practice, leading to uncertainty
about the universal value of PD-L1 expression levels as a
biomarker across tumor types [8–10]. The “Blueprint
PD-L1 IHC Comparability Project” was an effort to
compare the concordance of five antibody clones com-
monly used for assessing PD-L1 expression by IHC [11,
12]. The two-phase study revealed a good concordance
for three of the five antibody clones employed, but sug-
gests that interchanging assays and cutoffs would lead to
“misclassification” of PD-L1 status for some patients.
Furthermore, the use of FFPE archival tumor tissues
with non-standardized fixation and storage methods
may be a source of unpredictable and unintended results
for adequate PD-L1 antigen retrieval, potentially increas-
ing the heterogeneity of IHC intensity, extent and topog-
raphy of staining. All these factors complicate the use of
PD-L1 status as assessed by IHC for predicting patient
clinical response to ICIs [13, 14].
RNA-based assays on FFPE tissues are currently used in
the clinic to classify or predict recurrence risk in patients af-
fected by various tumor types, These assays include
DecisionDX-Melanoma (Castle Biosciences), Prosigna®
(Nanostring Technologies), MammaPrint® (Agendia),
Afirma® Thyroid FNA Analysis (Veracyte), and OncoType
DX® (Genomic Health) [15–19]. Most of these tests are
microarray- or quantitative reverse transcription
(qRT)-PCR-based assays specific for a small panel of
cancer-related genes. Recently, RNA-seq has emerged as
powerful tool to evaluate mRNA expression in the clinic
[20–23]. The use of highly-specific primers that target stably
expressed genes provides a high level of specificity and sensi-
tivity, allowing for the simultaneous measurement of several
targets including genes for sample quality control purposes.
Gene expression profiling by RNA-seq has minimal input
requirements and has the potential to be far more
cost-effective than IHC methods given the scalability of
next-generation sequencing. Further, strong concordance be-
tween platforms, including gene expression microarrays,
qRT-PCR and IHC has demonstrated the analytic validity of
RNA-seq, even for challenging FFPE tumor samples [24]. By
digitally counting target molecules, RNA-seq enables precise
transcriptome quantification that provides a continuum
measurement across a large dynamic range of expression.
The objective of this study was to compare RNA-seq
to IHC for the assessment of PD-L1, at both analytical
and clinical levels, with the intent to validate RNA-seq
as a predictor of response in 209 patients with multiple
tumor types treated with ICIs. To demonstrate the lin-
earity and sensitivity of PD-L1 RNA-seq as a standalone
assay, we tested several tumor samples across multiple
dilutions. We then used objective response criteria
(RECISTv1.1) to compare measurements of PD-L1 by
IHC versus RNA-seq to assess clinical utility.
Methods
Patients and clinical data
Eight collaborating institutions obtained approval by
their respective institutional review boards (IRBs) to
submit existing de-identified specimens and associated
clinical data for use in this study. Patients were identified
for inclusion of electronic pharmacy records indicated
they received at least one dose of checkpoint inhibition
therapy in the course of standard care, had adequate
pre-treatment FFPE tissue (minimum 10% tumor nuclei,
maximum 50% necrosis) collected within 2 years of first
dose, were evaluable for response by RECIST v.1.1, and
had known overall survival from first dose of checkpoint
blockade. A total of 209 patients were included, encom-
passing renal cell carcinoma (RCC, n = 45; 7 responders,
38 non-responders), metastatic cutaneous melanoma (n
= 76; 32 responders, 44 non-responders), and NSCLC (n
= 88; 17 responders, 71 non-responders). Our primary
clinical endpoint for analysis was objective response rate
(ORR), defined as patients with complete responses (CR)
or partial responses (PR), and patients with progressive
disease (PD) or stable disease (SD) classified as
non-responders (Additional file 1: Table S1) [25].
Immunohistochemical studies
In melanoma samples, PD-L1 expression was assessed
using the Dako Omnis platform (Agilent, Santa Clara, CA)
and the 28–8 pharmDx antibody (Agilent, Santa Clara,
CA), which is the FDA-approved complementary diagnos-
tic for nivolumab. For RCC and NSCLC samples, the 22c3
pharmDx antibody (Agilent, Santa Clara, CA) was
employed on Autostainer Link 48 (Agilent, Santa Clara,
CA), which is the FDA-approved companion diagnostic for
pembrolizumab. Established cutoffs for the diagnostics in
each histologic type were used to score PD-L1 IHC tumor
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proportion score (TPS) and immune cell staining (ICS) as
follows: melanoma TPS, 1%, [13] NSCLC TPS, 50 and 1%,
[7] RCC TPS, 1%; RCC ICS, 1%.
RNA-seq profiling
RNA was extracted from each sample following
microscopic tissue review by an anatomical patholo-
gist and selection of specimen representing tumor
cells and associated microenvironment. Gene expres-
sion was evaluated by targeted RNA-seq of 384 im-
mune transcripts using an analytically validated assay
[23]. Absolute reads were generated using Torrent
Suite’s plugin immuneResponseRNA (v5.2.0.0) and
further normalized to yield normalized reads per mil-
lion (nRPM), using previously described methods [23].
For all 394 genes including PD-L1, nRPM values were
subsequently ranked (gene expression rank) from 0 to
100 based on expression of these genes in a reference
population representing a wide range of gene expres-
sions in various tumor types, as previously described
[23]. A subset of samples with varying PD-L1 expres-
sion levels were serially diluted to demonstrate sensi-
tivity and linearity of detection.
Data analysis
To demonstrate the linearity of PD-L1 mRNA detec-
tion, coefficient of determination (R2) was calculated
for the absolute reads generated across various library
dilutions. To investigate the relationship between
PD-L1 expression by targeted RNA-seq and IHC, IHC
TPS and ICS results were categorized as either high
or low using the previously described FDA-approved
complementary and companion diagnostic scoring
guidelines and one-way ANOVA and Tukey honest
significant difference (HSD) was performed for all
PD-L1 values across all samples. To compare IHC
versus RNA-seq for prediction of response, values of
TPS ≥1% for melanoma, TPS ≥1% and ≥ 50% for
NSCLC, and TPS and ICS ≥1% for RCC were com-
pared to RNA-seq expression interpretations of high
(rank ≥75) and not-high (rank < 75), relative to a ref-
erence population. To compute sensitivity, specificity,
positive predictive value (PPV), negative predictive
value (NPV), and accuracy, a positive result was con-
sidered as IHC TPS of ≥1% for melanoma, TPS of
≥1% and ≥ 50% for NSCLC, and TPS and ICS ≥1% for
RCC, and high value for RNA-seq expression (rank
≥75). A negative result was considered as IHC TPS of
< 1% for melanoma, TPS of < 1 and < 50% for NSCLC,
and TPS and ICS < 1% for RCC, and a moderate or
low value for RNA-seq expression. Logistic regression
was then performed to evaluate the prediction of re-
sponse based on tumor type, IHC result, and
RNA-seq result.
Results
Linearity of PD-L1 assessment by RNA-seq
Linearity of PD-L1 assessment by RNA-seq was deter-
mined by comparing the absolute reads relative to an in-
put of 1.5625, 3.125, 6.25, 12.5, 25, and 50 pM RNA
library for tumor samples representing diverse levels of
expression (Fig. 1; Additional file 1: Table S2). Samples
#1 and #2 represent high expressors (PD-L1 > 75 rank),
while samples #3 and #4 represent moderate expressors
(PD-L1 = 25–75 rank). For samples #1 and #2, PD-L1
transcript detection values ranged from 0 to > 2400 ab-
solute reads, demonstrating a robust positive linear cor-
relation (R2 > 0.98) for clinical specimens expressing
high PD-L1 levels. For samples #3 and #4, PD-L1 tran-
script detection values ranged from 0 to < 450 absolute
reads, demonstrating a positive linear correlation (R2 >
0.98) for clinical specimens expressing low-to-moderate
PD-L1 levels. Overall, these results demonstrate that de-
tection of PD-L1 mRNA levels in FFPE samples by
RNA-seq is consistent across a dynamic range of expres-
sion, and that PD-L1 transcripts can be reliably quanti-
fied by a continuous variable of absolute transcript reads
down to values approaching background.
Analytical comparison of IHC and RNA-seq results
For the 209 samples evaluated, the highest rate of a posi-
tive result, defined as IHC TPS of ≥1% for melanoma,
TPS of ≥1% and ≥ 50% TPS for NSCLC, and TPS or ICS
≥1% for RCC, or RNA-seq rank ≥75, was observed with
NSCLC samples for both IHC and RNA-seq (Table 1).
One-way ANOVA demonstrated a statistically significant
correlation between PD-L1 RNA-seq rank and IHC
(TPS or ICS, p < 2e-16) across the three tumor types.
The null hypothesis, which specified that the means of
PD-L1 gene expression ranks in each IHC group would
not differ, was rejected. Therefore, we performed Tukey
HSD for multiple pairwise-comparisons between the
means of the IHC TPS/ICS high and not-high groups.
Ad-hoc Tukey’s HSD comparisons of NSCLC mean TPS
at < 1% (Fig. 2a), NSCLC TPS at < 50% (Fig. 2b), melan-
oma TPS at < 1% (Fig. 2c), and RCC TPS < 1% (Fig. 2d)
or ICS < 1% (Fig. 2e), demonstrated significant differ-
ences (p < 0.01) between the various groups that were
consistent with RNA-seq ranks.
Objective response rates
To investigate the clinical utility of a positive result for
PD-L1 by RNA-seq, IHC or both, we evaluated ORR in
RCC (n = 45), melanoma (n = 76), and NSCLC (n = 88)
patients receiving an FDA-approved ICI (Additional file
1: Table S1). For these comparisons, RNA-seq results
≤75 rank were combined into a single RNA-seq “not
high” group, enabling a more direct binary comparison
to IHC. The ORR for patients stratified by PD-L1 IHC
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levels was consistent with previously published values
for each tumor type [26–30] (Table 2), supporting
that our study population was not biased in selection,
and allowing for comparison of the IHC results to
those for RNA-seq.
ORR was 42.1% for melanoma, 15.6% for RCC, and
19.3% for NSCLC patients (Fig. 3 and Additional file 1:
Table S3). ORR, as measured by various PD-L1 measure-
ments, ranged from 37.9% (IHC < 1% TPS) to 72.7%
(RNA-seq high) for melanoma, 11.9% (RNA-seq low) to
42.1% (IHC > 50% TPS) for NSCLC, and 8.3% (RNA-seq
low) to 40.0% (IHC > 1% TPS) for RCC. For positive PD-L1
assessments across tumor types, the maximum ORR was
72.7% (RNA-seq) and 55.6% (IHC), 28.6% (RNA-seq) and
42.1% (IHC), and 33.3% (RNA-seq) and 40% (IHC) for mel-
anoma, NSCLC and RCC, respectively. Conversely, nega-
tive PD-L1 assessments resulted in ORR of 46.2%
(RNA-seq) and 37.9% (IHC) for melanoma, 11.9% (RNA--
seq) and 13–14% (IHC) for NSCLC, and 8.3% (RNA-seq)
and 12.5–14.6% (IHC) for RCC, with the latter two histolo-
gies’ ORR dependent on IHC cutoff and staining interpret-
ation. One important implication of assessing PD-L1 levels
is using negative results to support clinical decision making
against the administration of ICIs [29]. For RCC, the PPVs
for IHC TPS of ≥1% and for RNA-seq high were rather un-
certain due to the small population size. In melanoma, only
a low RNA-seq result had a notably high NPV (1.0–0.23 =
0.77). For NSCLC samples, neither test had much predict-
ive power for response (Fig. 3).
Fig. 1 PD-L1 transcript detection across serial dilutions of 4 tumor samples. PD-L1 transcript detection across serial dilutions of 4 tumor samples.
Results demonstrate high, moderate, and low PD-L1 expression and can be reliably quantified by a continuous variable of absolute transcript
reads. a Sample 1: Melanoma with high expression. b Sample 2: Melanoma with high expression. c Sample 3: RCC with moderate expression. d
Sample 4: RCC with moderate expression
Table 1 PD-L1 IHC and RNA-seq results for 209 samples
Test Result Test RCC Melanoma NSCLC
≥1% TPS IHC 5 (11%) 19 (25%) 38 (43%)
< 1% TPS IHC 40 (89%) 57 (75%) 50 (57%)
≥50% TPS IHC NA NA 19 (22%)
< 50% TPS IHC NA NA 69 (78%)
≥1% ICS IHC 4 (9%) NA NA
< 1% ICS IHC 41 (91%) NA NA
> 75 rank (high) RNA-seq 9 (20%) 11 (14%) 35 (40%)
25–75 rank (moderate) RNA-seq 24 (53%) 39 (51%) 42 (48%)
> 25 rank (low) RNA-seq 12 (27%) 26 (35%) 11 (12%)
Total 45 76 88
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Fig. 2 Ad-hoc Tukey’s HSD test comparing PD-L1 expression by RNA-seq (Y axis) with IHC (X axis). Box plots show concordance of the two
measurements across multiple clinical cutoffs for IHC and different tumor types. a NSCLC mean TPS at < 1%. b NSCLC mean TPS at < 50%. c
Melanoma TPS mean at < 1%. d RCC mean TPS < 1% or E) ICS < 1%
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Table 2 ORR across tumor type and individual biomarker result
Disease Test PD-L1 result Responders Non-responders Total ORR
Melanoma IHC TPS ≥1% 10 8 18 55.60%
< 1% 22 36 58 37.90%
RNA-seq High 8 3 11 72.70%
Moderate & low 24 41 65 46.20%
NSCLC IHC TPS ≥1% 10 28 38 26.30%
< 1% 7 43 50 14.00%
IHC TPS ≥50% 8 11 19 42.10%
< 50% 9 60 69 13.00%
RNA-seq High 10 25 35 28.60%
Moderate & low 7 46 53 11.90%
RCC IHC TPS ≥1% 2 3 5 40.00%
< 1% 5 35 40 12.50%
IHC ICS ≥1% 1 3 4 25.00%
< 1% 6 35 41 14.60%
RNA-seq High 3 6 9 33.30%
Moderate & low 4 32 36 8.30%
Fig. 3 Proportions of responses in subgroups defined by tests for PD-L1 expression. Objective response rate (ORR) was 42.1% for melanoma (Mel),
15.6% for renal cell carcinoma (RCC), and 19.3% for non-small cell lung carcinoma (NSCLC) (grey bars). Each complementary pair of subsets
corresponds to positive predictive value (PPV, solid line) and 1 – negative predictive value (NPV, dashed line) (circles). The intervals are 90%
confidence intervals. TPS-IHC = PD-L1 tumor proportion score (TPS) by IHC, rnaHigh TRUE = PD-L1 RNA-seq expression is high, rnaHigh FALSE =
PD-L1 RNA-seq expression is low or moderate (considered “negative”), rnaLow TRUE = PD-L1 RNA-seq expression is low, rnaLow FALSE = PD-L1
RNA-seq expression is moderate or high (considered “positive”)
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An important comparison of these two methodologies
is the ORR for concordant or discordant results when
combining RNA-seq and IHC PD-L1 expression results.
Concordant negative results (IHC/RNA-seq −/−) were
associated with the lowest observed ORR across all three
tumor types. Conversely, concordant positive results
(IHC/RNA-seq +/+) were not consistently associated
with the highest ORR. Although only four cases, dis-
cordant result between IHC and RNA-seq (IHC/RNA--
seq −/+) were associated with 75% ORR in melanoma,
(3 responders and 1 non-responder), the highest ORR of
any tumor. A high ORR was also documented amongst
NSCLC patients with discordant results (IHC/RNA-seq
+/−) at a ≥ 50% TPS cutoff (ORR = 66.7%), but not at a ≥
1% value (ORR = 20%) (Additional file 1: Table S4).
There were 34 patients treated with ipilimumab, 22 with
ipilimumab + nivolumab, and 153 with either
single-agent pembrolizumab, nivolumab, or atezolizu-
mab (anti-PD-1). For melanoma, a 67% response rate
was observed for patients with RNA-seq high treated
with an anti-CTLA4 agent, which increased to 80%
when analyzed for anti-PD-1 therapy alone. RCC (n =
10) and NSCLC (n = 2) had limited number of patients
treated with anti-CTLA4 agents, but RNA-seq high was
associated with the only RCC response to ipilimumab +
nivolumab, as well as non-response for all RNA-seq low
patients (Additional file 1: Table S5).
Clinical utility of PD-L1 IHC versus RNA-seq
Standard parameters of sensitivity, specificity, PPV, NPV,
and accuracy were used to compare the clinical utility of
PD-L1 assessment with IHC versus RNA-seq (Table 3).
RNA-seq in melanoma samples had the lowest sensitiv-
ity (25%) and the highest PPV (72.7%) of all test results.
The highest sensitivity at 58.8%, shared by both IHC
with TPS ≥1% and RNA-seq high in NSCLC samples,
was coupled with the lowest PPV at 26.3 and 28.6%, re-
spectively. High NPV (> 85%) was seen with IHC TPS
≥50% and RNA-seq in NSCLC samples, as well as with
IHC TPS ≥1% and RNA-seq in RCC samples. However,
PPV was suboptimal for all these biomarkers. Sensitivity,
specificity, PPV, and NPV for a double positive result
(IHC/RNA-seq +/+), as compared to a single positive re-
sult, was minimally different from direct comparisons
and offered little advantage. The results of these analyses
epitomize the typical trade-off of sensitivity for specifi-
city, and vice versa, with an overall less than optimal
performance of the tests to predict responders.
To evaluate RNA-seq as the gold standard and deter-
mine whether IHC adds predictive value, a logistic regres-
sion model was employed to evaluate the prediction of
response to treatment based on tumor type, PD-L1 by
IHC, and PD-L1 levels by RNA-seq (Table 4). As expected,
the model shows that melanoma patients (p = 0.0026)
have a higher response rate than patients with RCC and
NSCLC, and that the expression rank interpretation
(“RNA-seq”) has a significant linear (“RNA-seq.L”) rela-
tionship to response (equally spaced scoring from low to
moderate, and from moderate to high). The RNA-seq.L
estimate, 0.96, is the increase in the log odds of response
moving from low to moderate, or from moderate to high
(odds increased by a factor of 2.6, and by 6.8 going from
Low to High). There is no indication of a further quadratic
effect (“RNA-seq.Q”), but the sample size is small for de-
tecting such a departure from equal spacing. A model
examining whether the relationship between RNA-seq
and ORR varies by tumor type showed no significant
interaction (p = 0.80). A model examining whether the
PD-L1 RNA-seq and IHC results interact in predicting re-
sponse also showed no significant interaction (p = 0.45).
Table 3 Clinical utility comparison of IHC TPS and RNA-seq rank results
Prediction Method Sensitivity Specificity PPV NPV
Melanoma IHC ≥1% 31.3% 81.8% 55.6% 62.1%
Melanoma RNA-seq > 75 25.0% 93.2% 72.7% 63.1%
Melanoma IHC ≥1% & RNA-seq > 75 20.8% 94.6% 71.4% 64.8%
NSCLC IHC ≥1% 58.8% 60.6% 26.3% 71.4%
NSCLC IHC ≥50% 47.1% 84.5% 42.1% 87.0%
NSCLC RNA-seq > 75 58.8% 64.8% 28.6% 86.8%
NSCLC IHC ≥1% & RNA-seq > 75 63.6% 68.0% 30.4% 89.5%
NSCLC IHC ≥50% & RNA-seq > 75 46.2% 83.9% 37.5% 88.1%
RCC IHC ≥1% 28.6% 92.1% 40.0% 87.5%
RCC RNA-seq > 75 42.9% 84.2% 33.3% 88.9%
RCC IHC ≥1% & RNA-seq > 75 33.3% 93.9% 50.0% 88.6%
Sensitivity = TP/(TP + FN)
Specificity = TN/(TN + FP)
Positive predictive value (PPV) = TP/(TP + FP)
Negative predictive value (NPV) = TN/(TN + FN)
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Among the three tumor types analyzed in this study, the
only non-overlapping confidence interval for predicting
response was for “RNA-seq low vs high” in melanoma.
Discussion
PD-L1 appears as one of the most controversial biomarkers
to be introduced into clinical practice. Despite prior evi-
dence demonstrating that both technologic and histologic
variability limit clinical utility [31, 32], four IHC based tests
are currently approved for guiding treatment decisions in
patients with multiple tumor types. Clinicians, patients and
other stakeholders seeking reliable PD-L1 diagnostic assays
are subjected to the lack of IHC standardization and face
real implications to clinical care. Recently, the Blueprint
Working Group was established with cooperation from the
FDA, IHC platform vendors, professional oncology organi-
zations and the pharmaceutical industry to provide a com-
parison of different PD-L1 IHC tests in NSCLC, including
scoring methods for expression [11] . The initial findings
showed comparable results for 22C3, 28–8, and SP263 anti-
body clones, but reduced sensitivity for the SP142 clone,
when evaluating staining in tumor cells. In the phase 1
study, only 50% of the cases demonstrated concordant posi-
tive staining above the antibody specific cutoffs. These re-
sults are alarming given that the Blueprint study involved
pathologists with considerable expertise in NSCLC and the
utilization of large resection specimens (n = 38) that are typ-
ically easier to evaluate. While ‘no’ and ‘very high’ PD-L1 ex-
pression were mostly concordant, the Blueprint study
demonstrated that the ‘low’ to ‘intermediate’ expression
levels seen in most NSCLC patients can result in discrep-
ancy. In these instances, a continuous measure, rather than
using a specific TPS cutoff, may better predict ICI treatment
efficacy. The more recent phase 2 study [12] confirms the
previously reported differences in sensitivity between the
IHC assays, and reports reliability among pathologists ran-
ging from very strong for TPS scoring to poor for immune
cell scoring. Given the challenges associated with PD-L1
IHC, it is surprising the paucity of information that exists
for PD-L1 measurement in FFPE tumors by other methods.
In contrast to the Blueprint study, our study explores
measuring PD-L1 by a single alternative methodology,
RNA-seq by direct comparison between FDA-approved
PD-L1 IHC assays and a laboratory developed RNA-seq
test. Although previous studies demonstrate PD-L1 as
measured by IHC is a predictive biomarker of response
to ICIs [33], it was unclear if an alternative methodology
would validate PD-L1 utility as a predictive biomarker. It
was not the intent of this study to debate the clinical
utility of PD-L1 IHC, but to assess the clinical utility of
PD-L1 by RNA-seq. Unlike IHC, RNA-seq quantitates
the number of expressed mRNA transcripts in the entire
tumor microenvironment without subjective scoring
methods and cell type discrimination. When performed
in a CLIA laboratory setting with a validated protocol
[23], our data demonstrates that RNA-seq is a highly
sensitive and robust assay for measuring PD-L1 across a
continuum of expression levels.
Our study employed a considerably large (n = 209) co-
hort of samples from multiple institutions treated with
one or more FDA-approved ICIs. The specimens were
of variable tumor mass, including a large fraction of nee-
dle core biopsies and FNA cell blocks. Furthermore,
multiple tumor types were evaluated and the pathologist
reading IHC slides was not a renowned expert in any
one particular disease. In total, the study reflects a
real-world clinical scenario in which archival specimens
representing several commonly tested histologies are
evaluated for PD-L1 expression.
Data obtained from this study revealed that PD-L1 ex-
pression as measured by RNA-seq is highly correlated to
IHC both analytically and clinically. Overall, ICI re-
sponse varied between tumor types but as expected,
each demonstrated highest ORR with either a PD-L1
positive RNA-seq or IHC. We acknowledge that the
relatively small number of PD-L1 positive cases, espe-
cially RCC, may limit the evaluation of RNA-seq as a
predictive assay for the tumor types evaluated, but ORR
for patients stratified by PD-L1 IHC levels was consist-
ent with previously published values. Even with these
limitations however, RNA-seq high and low results for
melanoma demonstrates significant PPV and NPV, re-
spectively, and resulted in an overall 73% ORR com-
pared to 56% ORR by PD-L1 IHC. Although the
combined positive (IHC/RNA-seq +/+) samples were as-
sociated with an overall higher ORR than the combined
negative (IHC/RNA-seq −/−) samples, the highest ORR
of any tumor type were associated with discordant
Table 4 Logistic regression for predicting response category “CR or PR” versus “SD or “PD”
Estimate Std. Error z value Pr(>|z|)
TumorType RCC (reference) – – –
TumorType Melanoma (versus RCC) 1.50 0.50 3.01 0.0026
TumorType NSCLC (versus RCC) −0.13 0.53 −0.25 NS
IHC TPS ≥1% 0.41 0.40 1.03 NS
RNA-seq.L 0.96 0.40 2.43 0.015
RNA-seq.Q 0.21 0.28 0.76 NS
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melanoma IHC and RNA-seq results (IHC/RNA-seq
−/+). Given the small number of samples (n = 4) in this
grouping, a larger cohort with this phenotype is required
to understand if the predictive power is tumor type spe-
cific or a direct result of PD-L1 quantitation in melan-
oma by RNA-seq. NSCLC samples, which had the
largest number of PD-L1 positive RNA-seq and IHC
cases, did not however demonstrate predictive power for
either test. Most interesting is the ORR for combined
positive (IHC/RNA-seq +/+) and negative (IHC/RNA--
seq −/−) results. While a combined positive did not al-
ways demonstrate the highest ORR across tumor types,
the combined negative result did have the lowest ORR,
except for RCC IHC/RNA-seq +/− which was repre-
sented by only one case.
Unexpectedly, we found that melanomas with PD-L1
IHC TPS > 1% had a significantly improved response to
all ICI monotherapies, including anti-PD-1 and
anti-CLTA-4 monotherapy. We were also surprised to
find that elevated PD-L1 by RNA-seq quantification was
an even better predictor of response to the same mono-
therapies. This is a provocative finding given that the
PD-1/PD-L1 axis is currently thought to be entirely dis-
tinct and not interacting with the CTLA-4 axis [34].
However, we do acknowledge that our melanoma data
set is limited in size and this finding needs to be con-
firmed in future studies.
In addition to the inherent advantages of standardized
methods for PD-L1 assessment by RNA-seq, this tech-
nology is also convenient as it enables highly multi-
plexed testing of several patients in a single run, with
per sample costs approaching those of IHC when per-
formed in batch sizes greater than twenty. By measuring
multiple transcripts simultaneously, RNA-seq is well
suited to characterize the functional state of immune
cells in the tumor microenvironment for biomarkers of
antigen presentation, IFN-γ signaling, T-cell active cyto-
kines and other biological features that are responsive to
PD-1 checkpoint blockade. It is beyond the scope of this
study to report data for the focused set of nearly 400
other genes included in the transcriptome panel, how-
ever evaluating RNA for immune gene expression in
addition to PD-L1 has been shown to be predictive of ef-
ficacy to anti-PD-1 therapy across multiple tumor types
with more accuracy than PD-L1 IHC [35–37]. For ex-
ample, a T-cell inflamed signature based on IFN-γ genes
was associated with response to anti-PD-1 therapy in
multiple tumor types [35], and an algorithmic approach
which combines gene expression profiling with tumor
mutational burden (TMB) and PD-L1 IHC improves
prediction of response to ICIs in melanoma [37]. These
multi-marker approaches contribute more comprehen-
sive information to the cancer immunity cycle [38] than
a single analyte and could improve personalized
combination immunotherapy treatment options in pa-
tients that have failed prior immunotherapy by targeting
over-expressed immunomodulatory factors, including
LAG-3, GITR, ICOS, TIM-3, and OX40 [39] across mul-
tiple tumor types [40, 41]. Co-overexpression of PD-L1
and PD-L2 (another PD-1 ligand) in the same tumor, as
well as overexpression of other co-inhibitory or
co-activatory molecules can reliably indicate whether
checkpoint blockade is a significant factor in a specific
case [42, 43]. Though not presented here, RNA-seq may
enable a qualitative and quantitative analysis of tumor
infiltrating lymphocytes that inform on whether the
tumor is immunologically “hot” or “cold”, and provide
data to explore new biomarker opportunities [32].
For analytical purposes, the expression of other genes
has value relative to PD-L1 for use as an endogenous
control for PD-L1 normalization. It is feasible that the
various subjective IHC interpretation requirements for
estimating percentages of either tumor, immune or com-
bined cell staining could be replaced by normalization of
PD-L1 RNA-seq by cell specific markers. Normalization
against one or several markers, such as an immunohisto-
chemical stain which the surgical pathologist determines
to be highly specific for neoplastic cells in a given case,
CD45 for hematopoietic cells, CD3 for T-cells, CD8 for
cytotoxic T-cells, or CD68 for macrophages could result
in an objective qualitative PD-L1 result that can be auto-
mated to reproducibly report PD-L1 expression relative
to specific cell types in the tumor microenvironment.
With proper tissue review and selection, RNA-seq ana-
lysis of the tumor and associated microenvironment is
designed to provide a PD-L1 score minimally influenced
by sample selection bias and tumor heterogeneity, and
to minimize the current PD-LI testing variability which
may impact clinical decisions and the uptake of preci-
sion immune oncology treatments [44].
A major limitation of our study linked to development
of RNA-seq as a standardized measurement of PD-L1
expression, is a lack of external standards. In our study,
RNA-seq measurements have a proprietary method of
normalization that influence the results for all genes in
the panel. Our control samples and genes with a similar
impact are also proprietary. Additionally, the interpret-
ation of these measurements by rank is derived via com-
parison to a unique non-public reference database.
Although these are significant issues, the standardization
of PD-L1 measurement by RNA-seq is much more at-
tainable than in the case of IHC. External, publicly avail-
able standards could be developed and shared similarly
to how minimal residual disease for BCR-ABL has be-
come standardized [45]. Another limitation of this study
is its retrospective nature of testing archival specimens
to assess the presence of a dynamically upregulated bio-
marker which can change during the disease course.
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Therefore, PD-L1 status by RNA-seq needs to be further
validated in future prospective ICI clinical trials.
The confluence of the Blueprint study and our work
supports that alternative measurements of PD-L1 ex-
pression beyond IHC, such as RNA-seq, should be con-
sidered for clinical use to improve response prediction
in patients being considered to receive ICI treatments.
Conclusions
In summary, our study shows that measurement of
PD-L1 mRNA expression by RNA-seq is comparable to
PD-L1 expression by IHC assays, both analytically and
clinically, with evidence that for melanoma samples
RNA-seq may be superior to IHC. At minimum, mRNA
expression by RNA-seq provides another layer of PD-L1
detection which can exploited to predict tumor response
to ICI. The predictive performance of RNA-seq to meas-
ure PD-L1 expression (in comparison to IHC) is affected
to some extent by histologic factors, but the overall re-
sults suggest that moving forward with this technology
is a viable approach for this dynamic biomarker.
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